influenza
virus
continu
emerg
reemerg
caus
outbreak
epidem
occasion
pandem
influenza
vaccin
licens
public
use
gener
effect
season
influenza
issu
aris
product
immunogen
efficaci
case
vaccin
pandem
emerg
influenza
virus
highli
pathogen
avian
influenza
viru
particular
thu
need
improv
influenza
vaccin
vaccin
strategi
review
discuss
advanc
altern
influenza
vaccin
touch
briefli
licens
vaccin
vaccin
antigen
review
recombin
subunit
vaccin
viruslik
particl
vaccin
dna
vaccin
main
focu
virusvector
vaccin
approach
influenza
caus
signific
morbid
mortal
year
circul
season
influenza
virus
infect
world
popul
year
caus
averag
hospit
death
usa
everi
year
influenza
pandem
occur
sporad
throughout
histori
although
well
document
last
centuri
vari
degre
sever
notabl
spanish
flu
kill
estim
million
peopl
worldwid
influenza
infect
establish
protect
longterm
immun
featur
viru
make
vaccin
favor
choic
epidem
pandem
control
unfortun
protect
larg
limit
specif
strain
viru
ineffect
mutat
ie
drift
especi
shift
variant
antigen
chang
season
epidem
influenza
virus
requir
constant
surveil
circul
influenza
viru
strain
annual
review
potenti
reformul
new
vaccin
strain
match
circul
time
zoonot
influenza
surveil
work
toward
predict
potenti
pandem
influenza
virus
order
allow
product
vaccin
pandem
prepared
ha
current
primari
target
influenza
vaccin
high
affinityavid
neutral
receptorblock
antibodi
ha
glycoprotein
surfac
virion
effect
prevent
influenza
infect
suffici
haspecif
antibodi
titer
consid
protect
influenza
infect
thu
haspecif
antibodi
titer
classic
method
vaccin
efficaci
gaug
order
neutral
occur
maxim
vaccin
efficaci
circul
viru
strain
must
match
vaccin
strain
reason
season
vaccin
review
potenti
reformul
everi
year
epidem
strain
exhibit
antigen
drift
close
monitor
organ
select
prevail
strain
given
year
method
problemat
pandem
strain
emerg
quickli
often
without
warn
make
difficult
prepar
exactli
match
vaccin
viru
spread
exampl
first
identifi
north
america
earli
spring
monoval
vaccin
licens
septemb
largescal
vaccin
achiev
peak
second
wave
octob
delay
deliveri
vaccin
led
depart
health
human
servic
recommend
advanc
develop
nextgener
recombinantand
molecularbas
influenza
vaccin
addit
method
increas
breadth
strength
immun
adjuv
investig
use
vaccin
produc
use
tradit
method
anoth
approach
target
altern
highli
conserv
antigen
induc
heterosubtyp
immun
provid
crossprotect
respons
serolog
distinct
influenza
virus
benefit
includ
potenti
elimin
repeat
yearli
vaccin
season
influenza
well
increas
pandem
prepared
heterosubtyp
immun
conserv
viral
protein
demonstr
mous
model
number
differ
influenza
viru
strain
shown
longlast
protect
otherwis
lethal
influenza
challeng
number
altern
influenza
antigen
investig
potenti
induc
heterosubtyp
immun
includ
extern
na
glycoprotein
review
protein
np
conserv
intern
protein
polymeras
pa
recent
conserv
region
ha
stalk
also
identifi
target
potenti
heterosubtyp
vaccin
use
viral
vector
antigen
deliveri
express
key
method
achiev
nativ
express
mani
antigen
intern
influenza
antigen
particular
vaccin
remain
effect
method
influenza
prevent
control
popul
present
two
gener
type
influenza
vaccin
licens
clinic
use
season
influenza
usa
inactiv
vaccin
liveattenu
vaccin
laiv
intramuscularli
administ
inactiv
vaccin
common
licens
worldwid
although
licensur
laiv
coldadapt
use
season
influenza
grow
inactiv
vaccin
laiv
eggderiv
process
requir
averag
month
strain
choic
vaccin
administr
eu
influenza
vaccin
grown
culturedcel
line
licens
use
manufactur
novarti
review
reduc
pressur
eggbas
platform
us
eu
regulatori
agenc
requir
rigor
test
address
concern
regard
introduct
adventiti
oncogen
element
absenc
natur
filter
present
egg
review
alreadi
note
vaccin
must
tailor
specif
circul
strain
licens
monoval
vaccin
highli
pathogen
avian
influenza
viru
hpaiv
develop
use
current
eggbas
technolog
howev
method
present
number
problem
beyond
found
season
influenza
manufactur
beyond
safeti
concern
hpaiv
definit
virul
kill
embryo
inocul
egg
viru
reach
reason
high
titer
requir
effici
vaccin
develop
increas
requir
egg
gener
suffici
quantiti
antigen
vaccin
licens
vaccin
revers
genet
use
gener
reassort
vaccin
strain
ha
na
eggadapt
vaccin
product
backbon
ha
gene
also
modifi
remov
polybas
cleavag
site
associ
virul
beyond
product
concern
ha
virus
poorli
immunogen
compar
antigen
requir
sixtim
antigen
dose
two
immun
despit
limit
us
fda
approv
inactiv
subunit
vaccin
februari
use
event
pandem
effort
underway
gener
cellbas
hpaiv
vaccin
use
wildtyp
viru
met
reason
amount
success
review
unfortun
method
still
mani
issu
associ
inactiv
vaccin
revers
genet
use
gener
attenu
reassort
virus
use
seed
virus
avoid
propag
hpaiv
strain
recent
seed
virus
includ
celladapt
strain
oppos
eggadapt
strain
reduc
pressur
eggbas
vaccin
liveattenu
revers
genet
influenza
virus
also
gener
egg
cell
cultur
product
similar
seed
strain
inactiv
vaccin
virus
contain
immunogen
glycoprotein
hpaiv
ha
na
backbon
coldadapt
attenu
human
influenza
strain
could
use
gener
antigen
inactiv
vaccin
use
directli
laiv
immunomodul
adjuv
abil
enhanc
immunogen
vaccin
activ
innat
immun
system
directli
recruit
immun
mediat
vaccin
site
creat
antigen
depot
combin
thereof
habas
adjuv
vaccin
includ
phospholipid
oilinwat
emuls
squalenebas
novarti
glaxosmithklin
approv
use
europ
also
possibl
adjuv
vaccin
could
boost
crossreact
would
particularli
use
pandem
prepared
similarli
inactiv
vaccin
administ
aluminum
hydroxid
aluminum
phosphat
adjuv
demonstr
enhanc
immunogen
immunestimul
complex
iscom
repres
subclass
adjuv
iscom
compris
phospholipid
cholesterol
purifi
saponin
tree
quillaja
saponaria
molina
antigen
either
encapsul
lipid
structur
administ
tandem
iscom
gener
broad
robust
immun
respons
review
host
adjuv
influenza
vaccin
test
includ
tolllik
receptor
tlr
agonist
purifi
bacteri
protein
cytokin
chemokin
other
review
recombin
ha
proteinderiv
vaccin
also
develop
late
stage
clinic
trial
although
similar
split
subunit
vaccin
final
stage
problem
associ
eggand
mammaliancellbas
vaccin
develop
circumv
ha
select
vaccin
strain
clone
baculoviru
vector
use
infect
insect
cell
gener
insect
cell
express
ha
protein
interest
recombin
ha
protein
protein
purifi
use
formul
trival
vaccin
efficaci
safeti
demonstr
healthi
adult
older
popul
year
age
children
although
immunogen
reduc
children
compar
trival
inactiv
vaccin
viruslik
particl
vlp
review
noninfecti
nonrepl
particl
contain
immunolog
relev
viral
structur
gener
infect
cell
mammalian
insect
viru
vector
express
glycoprotein
andor
capsid
antigen
viru
interest
vlp
influenza
gener
express
ha
na
baculoviru
vector
vector
use
infect
yeast
mammalian
insect
cell
influenza
protein
spontan
assembl
bud
infect
cell
form
particl
resembl
wildtyp
virion
noninfecti
shown
protect
homolog
heterolog
hpaiv
challeng
ferret
dosedepend
manner
hpaiv
strain
vlp
also
produc
plant
nicotiana
benthiama
express
ha
low
pathogen
viru
well
ha
hpaiv
shown
immunogen
protect
low
dose
homolog
viru
challeng
well
heterolog
viru
challeng
boost
gener
vlp
consid
safe
consid
absenc
function
replic
machineri
dnabas
vaccin
review
short
bacteri
plasmid
contain
optim
mammalian
promot
drive
express
gene
interest
nucleotid
sequenc
cytidin
phosphat
guanosin
cpg
stimul
innat
immun
system
via
review
usual
select
marker
requir
product
plasmid
bacteria
administ
tradit
intramuscularli
plasmid
prime
immun
system
transfer
antigenpres
cell
either
direct
transfect
indirectli
transfect
muscl
cell
antigen
express
theoret
nativ
conform
gener
optim
antibodi
tcell
respons
moreov
plasmidvaccin
anim
shown
express
dna
vaccin
dendrit
cell
improv
tcell
global
vaccin
respons
dna
vaccin
potenti
induc
broad
longterm
immun
trial
anim
shown
promis
result
express
ha
na
due
lack
heterolog
protect
much
work
done
broaden
protect
express
conserv
antigen
consensusbas
ha
combin
thereof
dnabas
vaccin
target
conserv
sequenc
hpaiv
yield
partial
protect
hpaiv
challeng
although
result
clinic
trial
shown
promis
vaccin
achiev
level
protect
antibodi
multipl
administr
high
dose
like
part
due
insuffici
protein
express
dna
vaccin
also
test
number
pathogen
diseas
includ
sar
hiv
malaria
cancer
notabl
dna
vaccin
emerg
import
prime
agent
primeboost
regimen
primeboost
regimen
number
advantag
includ
greater
breadth
immun
humor
cellmedi
perhap
decreas
likelihood
escap
mutant
greater
antigen
recognit
genet
divers
human
popul
dna
vaccin
found
complement
virusvector
vaccin
well
primeboost
system
dna
vaccin
often
suffici
immunogen
viral
vector
suffer
preexist
immun
vector
case
prime
dna
vaccin
improv
antibodi
respons
monoval
inactiv
vaccin
given
week
dna
prime
virusvector
vaccin
main
focu
review
varieti
vector
virus
either
incap
replic
replic
without
caus
diseas
test
carrier
influenza
vaccin
antigen
viru
candid
studi
replic
nonrepl
form
includ
dna
virus
adenovirus
vaccinia
virus
poxvirus
primarili
replicationdefect
candid
positivestrand
rna
virus
alphavirus
attenu
chimer
flavirus
replic
vector
includ
baculoviru
assort
negativesens
negativestrand
rna
virus
nnsv
advent
revers
genet
nnsv
could
use
viral
vector
repres
major
field
studi
due
number
advantag
use
viru
vector
review
vector
includ
adenoassoci
virus
herpesvirus
relev
vector
influenza
outsid
scope
review
number
inher
advantag
use
virus
vaccin
vector
induc
protect
immun
virus
pathogen
well
viru
vector
abl
embodi
benefit
liveattenu
version
pathogen
especi
use
liveattenu
version
pathogen
feasibl
furthermor
viral
vector
chosen
engin
specif
target
certain
cell
popul
optim
prime
natur
relev
protect
respons
viru
vector
vaccin
also
import
compon
studi
primeboost
regim
especi
involv
dna
vaccin
prime
heterolog
primeboost
strategi
ie
prime
antigen
deliv
two
differ
method
dna
prime
follow
recombin
protein
virusvector
boost
shown
induc
improv
immun
compar
homolog
boost
howev
case
pandem
respons
primeboost
strategi
problemat
resourc
mass
vaccin
timelin
limit
prepandem
vaccin
propos
howev
identif
vaccin
strain
still
present
difficulti
well
linger
safeti
concern
viru
vector
develop
influenza
vaccin
review
basic
featur
platform
includ
featur
replic
antigen
express
describ
detail
efficaci
influenza
viru
infect
hpaiv
particular
provid
avail
inform
safeti
efficaci
human
includ
adenovirus
genu
mastadenoviru
dna
virus
respons
wide
rang
speciesspecif
diseas
caus
wide
rang
serotyp
adenovirus
extens
test
gene
deliveri
recombin
vaccin
use
safeti
concern
preexist
immun
complic
use
adenoviru
vector
recombin
adenovirus
rad
construct
replicationincompet
human
cell
although
also
use
replic
vector
abl
accommod
gene
insert
kb
depend
construct
delet
viral
gene
review
abl
express
insert
gene
vaccin
antigen
high
level
virus
grown
quickli
without
need
egg
qualifi
cell
line
design
use
replicationdefici
viru
adenovirus
infect
dendrit
cell
among
wide
rang
cell
lead
effici
antigen
present
immun
system
radvector
influenza
habas
vaccin
shown
immunogen
nonhuman
primat
pandem
viru
human
season
influenza
viru
strain
via
multipl
rout
administr
eg
epicutan
intranas
rad
also
test
vector
hpaiv
number
model
hoelscher
et
al
other
shown
replicationincompet
rad
express
ha
provid
protect
hpaiv
challeng
homolog
case
antigen
distinct
crossprotect
assort
influenza
strain
also
shown
use
rad
express
np
np
system
express
clade
clade
tandem
conserv
np
gene
cadvax
nextgener
rad
platform
involv
remov
certain
region
adenoviru
genom
allow
insert
multipl
target
gene
expand
possibl
antigen
express
holman
et
al
show
multipl
ha
antigen
na
express
togeth
nativ
form
nonhuman
rad
strain
also
investig
may
import
use
rad
vector
face
preexist
immun
rad
vector
use
influenza
vaccin
platform
number
virus
includ
hiv
hbv
sar
coronaviru
marburg
ebola
virus
west
nile
viru
dengu
viru
latter
four
util
cadvax
platform
rad
also
investig
field
cancer
vaccin
research
extens
studi
rad
vaccin
clinic
trial
particular
driven
advanc
develop
manufactur
practic
compar
viral
vector
vaccin
discuss
dna
viru
concern
viral
gene
could
integr
host
genom
adenoviru
seropreval
human
popul
anoth
area
concern
evid
mice
nonhuman
primat
human
indic
exist
antibodi
vector
might
interfer
vaccin
efficaci
especi
multipl
vaccin
differ
antigen
administ
could
reduc
initi
efficaci
well
prohibit
use
primeboost
system
use
vector
studi
indic
choos
serotyp
suffici
unlik
one
anoth
therebi
limit
crossreact
well
choos
strain
rare
human
popul
nonhuman
ad
strain
may
suffici
circumv
preexist
immun
reduc
vaccin
efficaci
studi
influenza
strategi
avoid
effect
preexist
immun
includ
increas
vaccin
dosag
altern
rout
administr
heterolog
primeboost
regimen
dnaprim
radboost
latter
shown
efficaci
protect
lethal
influenza
viru
challeng
includ
approach
potenti
work
similar
way
viral
vector
poxvirus
famili
larg
dsdna
virus
includ
smallpox
avipox
virus
canarypox
fowlpox
util
replicationdefici
viral
vector
poxvirus
larg
genom
capabl
maintain
larg
amount
transgen
materi
especi
avipox
virus
abl
infect
replic
human
cell
abl
express
larg
amount
transgen
often
use
promot
downsid
larg
genom
competit
antigen
present
pathway
replic
poxvirus
occur
cytoplasm
previous
discuss
elimin
chanc
viral
gene
integr
host
genom
although
replicationdefici
easili
grown
qualifi
cell
line
particular
emphasi
place
modifi
vaccinia
viru
ankara
mva
poxvirus
origin
studi
use
mva
vectorbas
vaccin
influenza
involv
insert
ha
np
gene
apuerto
circul
viru
recombin
mva
recmva
vector
shown
induc
neutral
antibodyand
ctlmediat
protect
recmva
also
explor
vaccin
hpaiv
shown
protect
mice
given
two
hightit
dose
nonhuman
primat
homolog
crossclad
challeng
multival
vaccinia
virusbas
vaccin
express
ha
na
np
induc
protect
neutral
antibodi
mice
adjuv
recent
recmva
express
conserv
antigen
np
test
human
shown
safe
highli
immunogen
although
protect
efficaci
assess
recmva
studi
extens
use
vaccin
hiv
well
virus
bacteria
eg
mycobacterium
tuberculosi
malaria
caus
plasmodium
spp
well
varieti
tumorassoci
antigen
cancer
immunotherapi
interestingli
allergi
extens
studi
recmva
vaccin
vector
combin
develop
smallpox
vaccin
give
clear
advantag
regard
manufactur
distribut
vaccinia
mva
vaccin
establish
stabil
data
store
lyophil
refriger
recent
novel
carbohydr
glass
storag
method
describ
viru
stabl
month
recmva
determin
safe
human
includ
immunocompromis
patient
alreadi
use
smallpox
vaccin
furthermor
unlik
adenovirus
repeat
vaccin
strain
possibl
preexist
antibodi
mva
appear
significantli
interfer
vaccin
efficaci
nonetheless
studi
investig
method
avoid
vectorspecif
preexist
immun
indic
use
primeboost
system
dna
viral
vector
review
immunomodul
aid
circum
vention
interfer
vectorbas
immun
similar
adenovirus
mucos
rout
vaccin
also
suggest
alphavirus
positivesens
ssrna
virus
togaviru
famili
zoonot
arthropodvector
virus
enter
human
popul
sporad
suggest
low
seropreval
replicationdefici
vector
express
high
amount
recombin
antigen
combin
low
seropreval
human
enabl
potent
immun
alphavirusvector
vaccin
typic
engin
nonrepl
replicon
particl
rp
vaccin
structur
gene
delet
attenu
rp
also
provid
room
insert
vaccin
antigen
gene
primari
immunogen
alphavirus
natur
target
dendrit
cell
replic
cytoplasm
deliv
vaccin
antigen
directli
immun
system
extrem
high
level
protein
express
combin
high
level
rna
produc
rp
vaccin
drive
activ
pathogenrecognit
receptor
induct
innat
immun
respons
selfadjuv
featur
make
rp
vaccin
highli
immunogen
moreov
rp
vaccin
also
induc
apoptosi
infect
cell
import
crossprim
immun
system
alphavirus
typic
use
rp
vaccin
develop
venezuelan
equin
enceph
viru
veev
sindbi
viru
sinv
semliki
forest
viru
veevsinv
chimera
sinv
express
ha
np
veev
express
ha
hpaiv
shown
effect
homolog
influenza
challeng
mice
chicken
respect
veevrp
also
test
express
na
hpaiv
chicken
mix
result
veevrp
express
ha
assort
influenza
strain
shown
immunogen
swine
alphaviru
vector
also
test
vaccin
number
virus
includ
hiv
hendra
nipah
use
gene
therapi
prophylaxi
tumor
drawback
use
alphavirus
includ
cytotox
well
difficulti
high
cost
associ
product
although
recombin
alphavirus
less
addit
positivesens
rna
virus
high
rate
recombin
compar
negativesens
rna
virus
rais
possibl
revers
wildtyp
reconstitut
infecti
viru
vaccin
product
present
safeti
concern
baculoviru
autographa
californica
multicapsid
nucleopolyhedroviru
acmnpv
natu
ralli
infect
insect
cell
capabl
transduc
mammalian
cell
cell
cultur
baculoviru
extens
use
recombin
protein
product
recent
shown
effect
vaccin
vector
unmodifi
acmnpv
infect
varieti
mammalian
cell
includ
human
cell
vari
effici
acmnpv
fuse
mammalian
cell
via
clathrindepend
endocytosi
deliv
genom
cytoplasm
gene
control
mammalian
promot
effici
express
infect
effici
variabl
baculoviru
pseudotyp
use
vesicular
stomat
viru
vsv
g
protein
develop
improv
tropism
transfect
effici
baculovirus
primarili
prime
innat
branch
immun
system
independ
fashion
shown
drive
strong
system
mucos
immun
respons
intranas
oral
administr
oral
rout
administr
appeal
altern
intranas
immun
prime
mucos
antibodi
respons
without
contraind
associ
person
respiratori
diseas
multipl
pseudotyp
baculovirus
develop
test
efficaci
influenza
viru
infect
pseudotyp
virus
envelop
virus
includ
foreign
glycoprotein
vsvgpseudotyp
acmnpv
encod
ha
hpaiv
express
cmv
promot
shown
induc
protect
immun
respons
mice
chicken
differ
approach
acmnpv
pseudotyp
use
ha
influenza
either
nativ
antigen
chimera
cytoplasm
domain
baculoviru
envelop
protein
pseudotyp
induc
hemagglutinationinhibit
antibodi
although
construct
contain
fulllength
ha
chimer
ha
effect
prime
humor
cellular
respons
mous
model
relat
studi
tetraval
pseudotyp
baculoviru
vaccin
four
ha
chimer
ha
protein
induc
potent
cellular
humor
respons
shown
protect
hpaiv
baculovirusvector
vaccin
influenza
still
preclin
stage
nnsv
order
mononegaviral
includ
paramyxovirus
paramyxoviruda
measl
viru
mump
viru
sendai
viru
newcastl
diseas
viru
ndv
human
respiratori
syncyti
rsv
metapneumovirus
human
parainfluenza
virus
parainfluenza
viru
filovirus
filovirida
ebola
marburg
virus
borna
diseas
viru
alon
famili
bornavirida
rhabdovirus
vsv
rabi
viru
famili
rhabdovirida
nnsv
recent
exploit
vaccin
vector
reli
develop
effici
revers
genet
techniqu
possibl
recov
nnsv
cdna
express
protein
requir
viral
transcript
replic
simultan
plasmid
encod
rna
genom
nnsv
share
number
featur
make
appeal
vaccin
vector
compar
positivestrand
rna
virus
nnsv
genom
stabl
exampl
recombin
express
gfp
maintain
express
gene
least
ten
gener
positivestrand
rna
virus
often
delet
insert
gene
quickli
nnsv
also
abl
accommod
larg
gene
insert
compar
potenti
vector
genom
maintain
rel
small
genom
competit
antigen
present
pathway
minim
genom
also
quit
simpl
well
understood
especi
compar
larg
complex
genom
found
poxvirida
famili
appeal
featur
nnsv
gene
transcript
gradient
wherebi
gene
closer
leader
sequenc
transcrib
abundantli
gene
distal
leader
sequenc
insert
gene
closer
promot
express
gene
interest
could
increas
consid
vaccin
product
nnsv
offer
number
addit
appeal
featur
virus
grown
high
titer
mani
cell
line
approv
vaccin
product
avoid
problem
associ
eggbas
manufactur
also
administ
intranas
provid
opportun
mucos
well
robust
system
immun
sever
nnsv
current
use
vaccin
develop
includ
vsv
number
virus
famili
paramyxovirida
discuss
detail
vsv
highli
lytic
nnsv
famili
rhabdovirida
vsv
primarili
infect
livestock
although
serotyp
infect
human
caus
primarili
mild
flulik
symptom
although
seriou
condit
enceph
also
report
appear
low
seropreval
area
world
howev
infect
induc
protect
neutral
antibodi
respons
envelop
glycoprotein
would
limit
use
homolog
primeboost
vsv
rel
small
genom
kb
accommod
insert
kb
moreov
vsv
incorpor
foreign
glycoprotein
surfac
virion
cellular
receptor
g
protein
thought
phosphatidylserin
ubiquit
compon
cell
plasma
membran
howev
controversi
despit
uncertainti
regard
receptor
vsv
infect
broad
rang
tissu
speci
addit
broad
tropism
vsv
stimul
strong
type
interferon
respons
interact
taken
togeth
featur
make
vsv
appeal
vaccin
vector
recombin
vsv
rvsv
express
ha
protein
assort
low
pathogen
influenza
virus
shown
protect
otherwis
lethal
challeng
includ
administ
postexposur
rvsv
express
influenza
np
shown
induc
robust
tcell
respons
although
protect
test
hpaiv
rvsv
express
induc
crossclad
neutral
antibodi
protect
similar
antigen
distinct
strain
take
advantag
increas
transcript
level
proxim
end
genom
vsv
author
insert
ha
gene
proxim
leader
sequenc
abl
show
steril
crossclad
immun
mice
use
primeboost
model
well
crossclad
neutral
antibodi
nonhuman
primat
rvsv
express
ha
hpaiv
shown
protect
challeng
chicken
vsv
test
vaccin
vector
mani
pathogen
includ
ebola
viru
rsv
hcv
hantaviru
tuberculosi
review
vsv
shown
particular
promis
potenti
hiv
vaccin
neurotrop
neurovirul
major
safeti
concern
vsv
natur
labadapt
strain
shown
neurovirul
rodent
attenu
strain
shown
less
neurovirul
nonhuman
primat
vsv
vaccin
hivinfect
nonhuman
primat
lead
develop
vsvmediat
diseas
safe
altern
investig
interestingli
replicationdefect
rvsv
develop
shown
immunogen
wildtyp
vaccin
vector
special
requir
growth
mutant
ie
complement
cell
line
could
limit
factor
mass
product
howev
number
paramyxovirus
explor
vector
candid
includ
measl
viru
newcastl
diseas
viru
human
parainfluenza
virus
measl
viru
test
vector
hiv
other
human
parainfluenza
virus
chimera
test
vaccin
vector
ebola
viru
rsv
pathogen
develop
influenza
vaccin
review
ndv
avian
paramyxoviru
genu
avulaviru
three
subgroup
ndv
strain
velogen
strain
extrem
virul
caus
system
infect
mesogen
strain
also
caus
system
infect
albeit
less
sever
lentogen
strain
primarili
restrict
respiratori
tract
attenu
use
liveattenu
vaccin
poultri
review
mesogen
lentogen
ndv
administ
nonhuman
primat
highli
attenu
appar
restrict
respiratori
tract
express
high
level
foreign
antigen
attribut
natur
hostrang
restrict
one
key
benefit
rndv
vaccin
rndv
grown
either
egg
cell
cultur
shown
grow
high
titer
vero
cell
influenza
ndv
problem
poultri
industri
dual
vaccin
appeal
particularli
vaccin
cost
must
kept
minimum
use
ndv
recombin
vaccin
vector
influenza
first
describ
use
recombin
lentogen
strain
express
ha
viru
vaccin
shown
protect
mice
challeng
vaccin
intraven
intraperiton
rndv
develop
express
ha
relev
poultri
industri
vaccin
provid
limit
protect
chicken
recent
rndv
shown
protect
lethal
challeng
two
group
veit
et
al
gener
rndv
express
ha
hpaiv
park
et
al
gener
rndv
express
ha
hpaiv
group
use
modifi
ha
construct
demonstr
effect
protect
chicken
hpaiv
challeng
subsequ
ndv
extens
studi
dualus
vaccin
vector
chicken
ndv
also
explor
human
use
recent
preclin
studi
liveattenu
mesogen
rndv
express
ha
hpaiv
gener
high
titer
neutral
antibodi
serum
follow
singl
intranas
intratrach
immun
nonhuman
primat
subsequ
rndv
express
ha
na
hpaiv
shown
protect
challeng
respiratori
immun
nonhuman
primat
intranas
pulmonari
aerosol
intratrach
experiment
model
deliveri
ndv
appeal
approach
needlefre
altern
could
problemat
patient
respiratori
ill
eg
asthma
ndv
also
shown
immunogen
capabl
induc
protect
immun
virus
includ
rsv
shown
immunogen
siv
sarscoronaviru
ebola
viru
also
emerg
candid
vector
cancer
therapi
review
ndv
serolog
distinct
human
paramyxovirus
thu
preexist
immun
vector
would
problem
although
vaccin
ndvvector
vaccin
gener
protect
immun
vector
unlik
repeat
use
vector
would
possibl
make
ndv
unlik
candid
influenza
vaccin
human
repeat
vaccin
requir
absenc
univers
influenza
vaccin
antigen
howev
may
use
singleus
pandem
vaccin
formerli
known
simian
viru
canin
parainfluenza
viru
paramyxoviru
genu
rubulaviru
prototyp
paramyxoviru
origin
isol
monkey
cell
cultur
although
sinc
determin
viru
wild
monkey
infect
wide
rang
speci
includ
human
appear
caus
diseas
possibl
except
associ
kennel
cough
canin
although
evid
scarc
interestingli
despit
lack
diseas
experiment
infect
dog
kennel
cough
vaccin
contain
live
use
dog
decad
importantli
risk
associ
vaccin
dog
kennel
cough
vaccin
identifi
veterinarian
pet
owner
capabl
infect
wide
rang
cell
type
includ
vaccineapprov
vero
cell
line
grow
high
titer
suggest
potenti
eggfre
lowcost
influenza
vaccin
altern
major
factor
distinguish
paramyxovirus
caus
limit
cytopath
effect
cell
abl
infect
nondivid
cell
recent
studi
suggest
may
caus
cytopath
effect
primari
cell
cultur
would
impact
vaccin
product
like
paramyxovirus
genom
gradient
gene
express
gene
locat
closest
leader
sequenc
greatest
level
express
gene
distal
leader
sequenc
express
much
lower
level
furthermor
pleomorph
structur
provid
flexibl
accommod
chang
size
genom
remov
mani
restrict
insert
size
seen
vector
taken
togeth
featur
make
appeal
vaccin
vector
first
describ
vaccin
vector
influenza
ha
human
influenza
viru
insert
near
end
genom
shown
protect
challeng
mous
model
infect
importantli
viru
express
ha
infect
cell
also
incorpor
ha
virion
recent
express
ha
hpaiv
also
describ
exploit
gradient
express
li
et
al
test
incorpor
ha
differ
locat
within
genom
ha
express
increas
transgen
insert
closer
leader
sequenc
howev
viral
fit
decreas
insert
site
closest
leader
sequenc
suggest
balanc
ha
express
disrupt
normal
gene
express
viru
fit
balanc
translat
differ
immunogen
although
vaccin
protect
lethal
hapiv
infect
singl
highdos
intranas
immun
mous
challeng
model
relat
studi
similar
vaccin
shown
incorpor
ha
virion
vaccin
protect
hpaiv
challeng
singl
immun
deliv
intranas
intramuscularli
provid
altern
rout
administr
singular
vaccin
moreov
inactiv
could
also
induc
antibodi
respons
although
boost
requir
unrel
influenza
express
vaccinia
viru
antigen
also
shown
induc
vaccinia
virusneutr
antibodi
partial
protect
vaccinia
viru
challeng
although
close
relat
human
parainfluenza
virus
antibodi
appear
neutral
although
complement
shown
play
role
aggreg
virion
lysi
suggest
could
use
repeatedli
case
season
influenza
vaccin
without
signific
loss
immunogen
result
crossreact
antibodi
vaccin
shown
safe
immunogen
mice
ferret
deliv
high
dose
intranas
sign
clinic
infect
viru
clear
lung
within
day
without
evid
system
infect
induc
minim
pathogenesi
furthermor
although
capabl
infect
human
convinc
reproduc
evid
caus
diseas
human
virusvector
vaccin
show
great
promis
nextgener
vaccin
howev
may
drawback
hurdl
overcom
depend
vaccin
viru
engin
influenza
strain
chang
ie
insert
new
ha
gene
match
emerg
influenza
strain
subtyp
may
simpl
could
alter
growth
characterist
vaccin
vector
also
consist
largescal
product
downstream
process
larg
unknown
newer
vaccin
vector
storag
stabil
also
concern
vaccin
includ
virusvector
liveattenu
vaccin
major
licens
vaccin
includ
liveattenu
inactiv
subunit
vaccin
requir
refriger
storag
licens
live
vaccin
lyophil
oral
polio
laiv
store
suspens
novel
virusvector
vaccin
describ
gener
store
frozen
suspens
laboratori
lyophil
preserv
techniqu
storag
refriger
warmer
temperatur
yet
explor
advanc
develop
adenovir
vacciniavector
mva
vaccin
except
lyophil
formul
test
clinic
trial
recent
stabil
method
describ
live
viru
vaccin
stabl
least
month
spraydri
sprayfreez
dri
similar
techniqu
also
develop
varieti
live
inactiv
viru
vaccin
thu
beyond
efficaci
mani
aspect
novel
virusvector
vaccin
studi
consid
novel
vaccin
pandem
influenza
new
approach
share
one
featur
licens
manufactur
enorm
challeng
current
inactiv
season
vaccin
provid
infrastructur
process
develop
product
approv
deliveri
inactiv
pandem
vaccin
moreov
manufactur
approv
develop
distribut
inactiv
season
influenza
vaccin
streamlin
approv
process
licensur
howev
even
wellestablish
process
fail
meet
necessari
pandem
vaccin
product
timelin
major
vaccin
deliv
peak
pandem
ongo
pandem
prepared
effort
includ
increas
capac
eggand
cellbas
vaccin
product
well
continu
effort
streamlin
vaccin
licensur
novel
vaccin
vaccin
strategi
describ
advantag
establish
pipelin
develop
manufactur
approv
without
prior
approv
would
abl
address
pandem
new
vaccin
requir
either
develop
pandem
vaccin
stockpil
prepandem
vaccin
initi
develop
season
influenza
vaccin
three
altern
share
need
extens
clinic
develop
requir
strong
govern
partnership
expect
market
engag
industri
virusvector
vaccin
addit
concern
mani
benefit
associ
virusvector
vaccin
requir
threshold
replic
vaccin
individu
preexist
immun
vaccine
prevent
effect
vaccin
demonstr
extens
rad
vaccin
mani
virusvector
vaccin
demonstr
efficaci
presenc
preexist
vector
immun
anim
model
howev
promis
result
may
translat
human
clinic
modif
vaccin
strategi
eg
primeboost
regimen
increas
vaccin
dose
could
reduc
origin
benefit
virusvector
vaccin
exist
vaccin
although
current
licens
influenza
vaccin
gener
efficaci
match
circul
influenza
virus
constant
evolut
season
influenza
virus
regular
emerg
novel
influenza
virus
reduc
effect
strain
limit
current
vaccin
product
capac
adjuv
technolog
offer
opportun
improv
efficaci
reduc
antigen
dose
current
inactiv
vaccin
safeti
concern
inher
limit
inactiv
vaccin
limit
use
new
approach
need
recombin
viru
vector
offer
varieti
new
approach
effect
vaccin
influenza
viru
virusvector
vaccin
provid
appeal
approach
next
gener
influenza
vaccin
recombin
viru
vector
mani
promis
featur
includ
opportun
robust
cell
culturebas
product
flexibl
formul
deliveri
method
modul
innat
adapt
immun
respons
opportun
express
engin
viral
antigen
approach
includ
dna
vlp
recombin
protein
vaccin
also
potenti
improv
influenza
vaccin
efficaci
particularli
combin
viru
vector
primeboost
strategi
howev
beyond
need
confirm
safeti
mani
vaccin
limit
mean
effect
assess
efficaci
current
surrog
end
point
accept
approv
influenza
vaccin
usa
induct
defin
increas
hemagglutinationinhibit
serum
antibodi
licens
laiv
could
meet
end
point
requir
demonstr
efficaci
ongo
effort
better
defin
efficaci
immun
respons
influenza
vaccin
program
need
expand
includ
nextgener
vaccin
compar
multifacet
respons
inactiv
vaccin
liveattenu
vaccin
natur
infect
comprehens
understand
human
immun
respons
infect
vaccin
associ
surrog
end
point
enabl
better
design
preclin
analysi
upandcom
influenza
vaccin
beyond
vaccin
describ
futuregener
vaccin
alreadi
earli
stage
develop
cut
edg
approach
explor
reflect
rapidli
expand
field
hostpathogen
interact
exampl
new
liveattenu
vaccin
engin
modul
viru
host
cell
respons
regul
mirna
express
delet
mirna
seed
site
incorpor
mirna
vaccin
virus
modifi
viru
replic
host
immun
respons
two
approach
engin
new
vaccin
second
strategi
improv
influenza
vaccin
involv
ration
modif
glycosyl
viru
glycoprotein
modifi
immunogen
immunodomin
vaccin
antigen
final
specif
influenza
recent
discoveri
human
antibodi
bind
conserv
stalk
region
ha
neutral
multipl
subtyp
influenza
viru
review
open
door
new
approach
hatarget
vaccin
design
one
approach
test
plasmidexpress
headless
ha
headless
ha
vlp
prime
respons
conserv
stalk
antigen
similar
approach
best
achiev
use
recombin
virusvector
vaccin
effect
deliv
engin
antigen
headless
ha
prime
robust
durabl
broadli
reactiv
antibodi
respons
paper
special
note
highlight
influenza
season
influenza
caus
signific
morbid
mortal
year
pandem
influenza
constant
threat
influenza
gener
well
control
yearli
vaccin
howev
current
eggbas
approach
limit
particularli
emerg
virus
pandem
neutral
antibodi
form
hemagglutinin
ha
glycoprotein
thu
vaccin
base
ha
antigen
although
nonneutr
less
immunogen
subimmunodomin
conserv
offer
possibl
broader
even
heterosubtyp
protect
recent
human
monoclon
antibodi
studi
suggest
conserv
region
ha
may
avail
univers
neutral
vaccin
target
licens
vaccin
use
season
influenza
includ
inactiv
intramuscular
vaccin
liveattenu
vaccin
must
reevalu
annual
strain
specif
licens
vaccin
monoval
split
inactiv
vaccin
similar
season
influenza
vaccin
howev
poorli
immunogen
requir
sixtim
antigen
dose
deliv
two
immun
approxim
efficaci
revers
genet
techniqu
use
gener
attenu
seed
virus
immunomodul
enhanc
immunogen
vaccin
directli
activ
innat
immun
system
recruit
immun
mediat
vaccin
site
recombin
protein
eg
baculovirusexpress
protein
use
produc
ha
antigen
subunit
vaccin
viruslik
particl
mimic
wildtyp
virion
noninfecti
nonrepl
particl
viruslik
particl
may
improv
immunogen
compar
subunit
vaccin
dna
vaccin
bacteri
plasmid
contain
strong
mammalian
promot
gene
interest
plasmid
prime
immun
system
transfect
host
cell
virusvector
vaccin
develop
varieti
infecti
diseas
includ
influenza
good
safeti
profil
virusvector
vaccin
offer
distinct
advantag
vaccin
approach
includ
hightit
product
capac
cell
cultur
express
engin
nativ
antigen
express
multipl
antigen
adjuv
multipl
formul
option
end
point
assess
vaccin
efficaci
serum
antibodi
hemagglutin
inhibit
titer
need
effect
develop
assess
nextgener
vaccin
new
develop
understand
hostpathogen
interact
regul
induct
effect
immun
respons
lead
toward
new
vaccin
strategi
ha
stalk
antigen
ration
glycosyl
mirna
regul
three
approach
futur
vaccin
mani
cuttingedg
approach
requir
viru
vector
effect
implement
emphas
need
develop
viralvector
vaccin
